Broadfin Capital LLC raised its position in Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) by 8.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,791,590 shares of the company’s stock after buying an additional 384,600 shares during the period. Aralez Pharmaceuticals comprises about 2.3% of Broadfin Capital LLC’s portfolio, making the stock its 13th largest position. Broadfin Capital LLC owned about 7.32% of Aralez Pharmaceuticals worth $21,131,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Dynamic Technology Lab Private Ltd acquired a new stake in Aralez Pharmaceuticals during the fourth quarter worth $103,000. Shufro Rose & Co. LLC raised its stake in Aralez Pharmaceuticals by 30.3% in the third quarter. Shufro Rose & Co. LLC now owns 21,487 shares of the company’s stock worth $104,000 after buying an additional 5,000 shares in the last quarter. J. Goldman & Co LP purchased a new stake in Aralez Pharmaceuticals during the fourth quarter worth approximately $198,000. Nwam LLC purchased a new stake in Aralez Pharmaceuticals during the third quarter worth approximately $228,000. Finally, FNY Managed Accounts LLC raised its stake in Aralez Pharmaceuticals by 13.5% in the third quarter. FNY Managed Accounts LLC now owns 59,000 shares of the company’s stock worth $286,000 after buying an additional 7,000 shares in the last quarter. 44.01% of the stock is currently owned by hedge funds and other institutional investors.

Institutional Ownership by Quarter for Aralez Pharmaceuticals (NASDAQ:ARLZ)

Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ) traded down 2.38% during midday trading on Thursday, hitting $4.52. 329,121 shares of the stock were exchanged. The company’s 50 day moving average is $4.36 and its 200-day moving average is $4.74. Aralez Pharmaceuticals Inc. has a 1-year low of $3.10 and a 1-year high of $6.80. The stock’s market cap is $295.73 million.

“Broadfin Capital LLC Raises Stake in Aralez Pharmaceuticals Inc. (ARLZ)” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and republished in violation of United States and international copyright and trademark law. The correct version of this piece can be accessed at http://www.dailypolitical.com/2017/02/16/broadfin-capital-llc-raises-stake-in-aralez-pharmaceuticals-inc-arlz.html.

A number of research firms have recently commented on ARLZ. Bloom Burton reaffirmed an “accumulate” rating on shares of Aralez Pharmaceuticals in a research note on Tuesday, November 8th. Chardan Capital set a $10.00 price objective on shares of Aralez Pharmaceuticals and gave the company a “buy” rating in a research note on Tuesday, November 8th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Aralez Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $10.33.

In related news, Director Robert Paul Harris sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, November 28th. The shares were sold at an average price of $4.65, for a total value of $93,000.00. Following the sale, the director now directly owns 614,094 shares of the company’s stock, valued at $2,855,537.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 6.77% of the company’s stock.

About Aralez Pharmaceuticals

Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.

5 Day Chart for NASDAQ:ARLZ

Want to see what other hedge funds are holding ARLZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ).

Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.